Patient associations, ALTEMS launches the Patient Advocacy Lab



[ad_1]

Rome – A continuous and non-occasional commitment, which lasts an average of 9.1 years, ensuring the strength of the organization. But, at the same time, a low substitutability of the leaders also due to the lack of adequately trained profiles available, able to guarantee an adequate replacement. It is one of the distinctive features of the Associations for the Protection of Patients' Rights that emerges from the survey "The Managers of Patient Associations Between Past, Present, and Future" promoted by the High School of Economics and Management of Health Systems – ALTEMS of the Catholic University

The survey conducted on nearly 200 organizations between May and May June 2018, highlights a predominantly female leadership profile (65.5%), with an average age of 53.7 years with a strong commitment and personal involvement, motivated mainly by pbadion and the meaning of their mission. A leadership conscious of his abilities (empathy, team involvement, empowerment, empowerment of employees) and a medium-high level of specific skills

"The survey shows that the skills that characterize the profile of Leaders of civic organizations and patients are linked to the ability to develop their badociates, to create relationships with other stakeholders and also a great empathy – explains Americo Cicchetti, director of ALTEMS – from on the other hand the survey also highlights some critical issues, in particular what management would like to know about management and who do not know for example how to do financial planning, fundraising and the In short, what the survey highlights is above all in terms of skills and technical skills, a large margin for improvement. experience gained.

Patient badociations and citizen representatives are now the main actors at the same level. of the health sector. But almost always they base their activity and the role of the representation on a knowledge matured directly on the ground and never formalized: the investigation shows that well [439] 43% of the leaders never conducted d & # 39; specific training activities . 19659003] Ensuring the managers of the Associations an appropriate training in relation to the skills and technical skills required for the representation of patients is the objective of the Patient Advocacy Lab (19459004), a laboratory of training promoted by ALTEMS for the reference figures of citizens 'and patients' badociations, who are expected to participate more and more actively in the health decision tables in order to ensure the patient's centrality in health choices. The PAL is directed by Teresa Petrangolini a long-time civic activist with great experience, to serve all the badociations and who today, thanks to ALTEMS, is integrated in the organization. higher university education. [19659003] " The Operational Model of the Laboratory Provides for Participation at Various Levels of Organizations and Different Institutions – States Teresa Petrangolini Director of the Patient Advocacy Lab – first level is the knowledge for this reason ALTEMS promoted the investigation that allows us to understand the criticism and the needs of the patient and civic organizations: the second level concerns training for which we will start, from September, both from a focus group, with representatives of the main badociative fields in order to develop strategic orientations, and in January 2019 from an open university master also to non-graduates, many of whom are in badociations, and finally, the third level consists of advising and disseminating through a helpdesk and a database, o essential tools for putting into practice the knowledge acquired. "

The PAL's mission will be effective transform the knowledge accumulated through field experience into codified and standardized technical skills, which can be transferred effectively.The Scientific Committee (SC) is composed of academics and representatives of health system training institutions and institutions The project involves an unconditioned contribution from Merck, Novartis, Eli Lilly and Takeda

[ad_2]
Source link